You are here

  • Home
  • Archive
  • Volume 107, Issue 2
  • Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years

Article metrics

Article menu

Download PDFPDF

PostScript
Letter
Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12–15 years
Free

 

Online download statistics by month:

Online download statistics by month: August 2021 to March 2023

AbstractFullPdf
Aug 202117811773209
Sep 202121822137294
Oct 2021828809139
Nov 2021628602109
Dec 202147146879
Jan 2022682675102
Feb 2022623631135
Mar 202233735471
Apr 202219920151
May 202219920348
Jun 202211411155
Jul 202211412147
Aug 2022929147
Sep 202211910734
Oct 2022817922
Nov 2022717028
Dec 2022888727
Jan 2023686620
Feb 2023464527
Total872386301544